Lek Shareholders did not Approve the Proposed Modifications to the Statute
Lek Pharmaceuticals d. d. announces that the resolutions proposed at today’s Extraordinary General Meeting of shareholders have not been approved. In the announcement regarding its intention to make an offer for Lek, Novartis reserved the right not to proceed with the making of a formal offer for Lek in the event the resolutions proposed at today’s Extraordinary General Meeting were not approved.
Upon the conclusion of the General Meeting, Mr. Dragonja, President of Board of Management of Lek, said: “We are clearly disappointed at the outcome of the shareholders’ meeting which did not give its approval for the resolutions proposed by the Board of Management and the Supervisory Board. This new situation will necessitate re-consideration of the further implementation of the company’s strategic plan with a view to maintaining a strong market position both in terms of its product portfolio and product pipeline, thus meeting its stakeholders’ expectations.”
This press release contains statements and conclusions based on projections of Lek’s future business operations. These estimates are derived from the best information currently available. In case these forecasts prove unreliable, the actual results could prove different from those projected.
- * *
For additional information, please contact:
Misa Komar – Ziberna, Lek’s Corporate Communications
Telephone: + 386 1 580 22 43